{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:58:59Z","timestamp":1794887939766,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with \u226520 nodules and severe itch uncontrolled with topical therapies. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13. Patients were randomized 1:1 to 300\u2009mg dupilumab or placebo subcutaneously every 2\u2009weeks for 24\u2009weeks. The primary endpoint was pruritus improvement, measured by proportion of patients with a \u22654-point reduction in Worst Itch Numeric Rating Scale (WI-NRS) from baseline at week 24 (PRIME) or week 12 (PRIME2). Key secondary endpoints included nodule number reduction to \u22645 at week 24. PRIME and PRIME2 enrolled 151 and 160 patients, respectively. Both trials met all the pre-specified primary and key secondary endpoints. A \u22654-point WI-NRS reduction at week 24 in the dupilumab and placebo arms was achieved by 60.0% and 18.4% of patients, respectively, in PRIME (95% confidence interval (CI), 27.8\u201357.7 for the difference,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and at week 12 by 37.2% and 22.0% of patients, respectively, in PRIME2 (95% CI, 2.3\u201331.2;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.022). Dupilumab demonstrated clinically meaningful and statistically significant improvements in itch and skin lesions versus placebo in PN. Safety was consistent with the known dupilumab safety profile.\n                  <\/jats:p>\n                  <jats:p>\n                    ClinicalTrials.gov identifiers:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04183335\">NCT04183335<\/jats:ext-link>\n                    and\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04202679\">NCT04202679<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02320-9","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:02:03Z","timestamp":1683201723000},"page":"1180-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":254,"title":["Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials"],"prefix":"10.1038","volume":"29","author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mollanazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert W.","family":"Staudinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naimish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9968-1517","authenticated-orcid":false,"given":"John T.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang, A. H., Williams, K. A. & Kwatra, S. G. Prurigo nodularis: epidemiology and clinical features. J. Am. Acad. Dermatol. 83, 1559\u20131565 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah, S. et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J. Am. Acad. Dermatol. 84, 747\u2013760 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.21032","volume":"187","author":"CLI Morgan","year":"2022","unstructured":"Morgan, C. L. I. et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br. J. Dermatol. 187, 188\u2013195 (2022).","journal-title":"Br. J. Dermatol."},{"key":"2320_CR4","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin, M. et al. Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a population-based claims data analysis. J. Eur. Acad. Dermatol. Venereol. 35, 2270\u20132276 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2320_CR5","doi-asserted-by":"crossref","first-page":"adv00155","DOI":"10.2340\/00015555-3518","volume":"100","author":"A Ryczek","year":"2020","unstructured":"Ryczek, A. & Reich, A. Prevalence of prurigo nodularis in Poland. Acta Derm. Venereol. 100, adv00155 (2020).","journal-title":"Acta Derm. Venereol."},{"key":"2320_CR6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/jcm11010095","volume":"11","author":"Y-R Woo","year":"2021","unstructured":"Woo, Y.-R., Wang, S., Sohn, K.-A. & Kim, H.-S. Epidemiology, comorbidities and prescription pattern of Korean prurigo nodularis patients: a multi-institution study. J. Clin. Med. 11, 95 (2021).","journal-title":"J. Clin. Med."},{"key":"2320_CR7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","volume":"141","author":"S Wongvibulsin","year":"2021","unstructured":"Wongvibulsin, S. et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J. Invest. Dermatol. 141, 2530\u20132533 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"2320_CR8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang, A. H., Canner, J. K., Khanna, R., Kang, S. & Kwatra, S. G. Real-world prevalence of prurigo nodularis and burden of associated diseases. J. Invest. Dermatol. 140, 480\u2013483 (2020).","journal-title":"J. Invest. Dermatol."},{"key":"2320_CR9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/jdv.16929","volume":"35","author":"C Zeidler","year":"2021","unstructured":"Zeidler, C. et al. The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: a comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort. J. Eur. Acad. Dermatol. Venereol. 35, 738\u2013743 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2320_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","volume":"79","author":"S Steinke","year":"2018","unstructured":"Steinke, S. et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology network on assessment of severity and burden of pruritus (PruNet) cross-sectional trial. J. Am. Acad. Dermatol. 79, 457\u2013463 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","volume":"27","author":"A Iking","year":"2013","unstructured":"Iking, A. et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J. Eur. Acad. Dermatol. Venereol. 27, 550\u2013557 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2320_CR12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal, P. et al. Clinical characteristics and disease burden in prurigo nodularis. Clin. Exp. Dermatol. 46, 1277\u20131284 (2021).","journal-title":"Clin. Exp. Dermatol."},{"key":"2320_CR13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bjd.20957","volume":"186","author":"S Wongvibulsin","year":"2022","unstructured":"Wongvibulsin, S. et al. Latent class analysis identification of prurigo nodularis comorbidity phenotypes. Br. J. Dermatol. 186, 903\u2013905 (2022).","journal-title":"Br. J. Dermatol."},{"key":"2320_CR14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/ced.14652","volume":"46","author":"N Sutaria","year":"2021","unstructured":"Sutaria, N. et al. Association of prurigo nodularis and infectious disease hospitalizations: a national cross-sectional study. Clin. Exp. Dermatol. 46, 1236\u20131242 (2021).","journal-title":"Clin. Exp. Dermatol."},{"key":"2320_CR15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2019.03.083","volume":"81","author":"VA Larson","year":"2019","unstructured":"Larson, V. A. et al. Association between prurigo nodularis and malignancy in middle-aged adults. J. Am. Acad. Dermatol. 81, 1198\u20131201 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000246715","volume":"190","author":"M Tanaka","year":"1995","unstructured":"Tanaka, M., Aiba, S., Matsumura, N., Aoyama, H. & Tagami, H. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 190, 269\u2013276 (1995).","journal-title":"Dermatology"},{"key":"2320_CR17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","volume":"79","author":"E Boozalis","year":"2018","unstructured":"Boozalis, E. et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J. Am. Acad. Dermatol. 79, 714\u2013719 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR18","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","volume":"5","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder, S. et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 5, e42 (2020).","journal-title":"Itch"},{"key":"2320_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams, K. A. et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev. Clin. Pharmacol. 14, 67\u201377 (2021).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2320_CR20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","volume":"80","author":"AA Qureshi","year":"2019","unstructured":"Qureshi, A. A., Abate, L. E., Yosipovitch, G. & Friedman, A. J. A systematic review of evidence-based treatments for prurigo nodularis. J. Am. Acad. Dermatol. 80, 756\u2013764 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","volume":"82","author":"HF St\u00e4nder","year":"2020","unstructured":"St\u00e4nder, H. F., Elmariah, S., Zeidler, C., Spellman, M. & St\u00e4nder, S. Diagnostic and treatment algorithm for chronic nodular prurigo. J. Am. Acad. Dermatol. 82, 460\u2013468 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaad.2016.05.035","volume":"75","author":"NK Mollanazar","year":"2016","unstructured":"Mollanazar, N. K. et al. Retrospective analysis of data from an itch center: integrating validated tools in the electronic health record. J. Am. Acad. Dermatol. 75, 842\u2013844 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams, K. A., Huang, A. H., Belzberg, M. & Kwatra, S. G. Prurigo nodularis: pathogenesis and management. J. Am. Acad. Dermatol. 83, 1567\u20131575 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2320_CR24","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s044lbl.pdf (2019)."},{"key":"2320_CR25","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf (2022)."},{"key":"2320_CR26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2340\/00015555-3243","volume":"99","author":"ZZ Almustafa","year":"2019","unstructured":"Almustafa, Z. Z., Weller, K., Autenrieth, J., Maurer, M. & Metz, M. Dupilumab in chronic prurigo: a case series and literature review. Acta Derm. Venereol. 99, 905\u2013906 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"2320_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamadermatol.2018.3906","volume":"155","author":"NK Mollanazar","year":"2019","unstructured":"Mollanazar, N. K., Elgash, M., Weaver, L., Valdes Rodriguez, R. & Hsu, S. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 155, 121\u2013122 (2019).","journal-title":"JAMA Dermatol."},{"key":"2320_CR28","first-page":"e13222","volume":"33","author":"JG Holm","year":"2020","unstructured":"Holm, J. G., Agner, T., Sand, C. & Thomsen, S. F. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol. Ther. 33, e13222 (2020).","journal-title":"Dermatol. Ther."},{"key":"2320_CR29","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald, L. E. et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc. Natl Acad. Sci. USA 111, 5147\u20135152 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2320_CR30","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153\u20135158 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2320_CR31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder, S. et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J. Eur. Acad. Dermatol. Venereol. 36, 573\u2013581 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2320_CR32","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","volume":"156","author":"M Kimel","year":"2020","unstructured":"Kimel, M., Zeidler, C., Kwon, P., Revicki, D. & St\u00e4nder, S. Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 156, 1354\u20131358 (2020).","journal-title":"JAMA Dermatol."},{"key":"2320_CR33","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2340\/00015555-3332","volume":"99","author":"C Riepe","year":"2019","unstructured":"Riepe, C. et al. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm. Venereol. 99, 1288\u20131290 (2019).","journal-title":"Acta Derm. Venereol."},{"key":"2320_CR34","doi-asserted-by":"crossref","first-page":"adv00401","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler, C., Pereira, M. P., Augustin, M., Spellman, M. & St\u00e4nder, S. Investigator\u2019s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm. Venereol. 101, adv00401 (2021).","journal-title":"Acta Derm. Venereol."},{"key":"2320_CR35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira, M. P. et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J. Eur. Acad. Dermatol. Venereol. 32, 1059\u20131065 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2320_CR36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay, A. Y. & Khan, G. K. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","journal-title":"Clin. Exp. Dermatol."},{"key":"2320_CR37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo, Y., Thomas, C. L., Harrison, M. A., Salek, M. S. & Finlay, A. Y. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J. Invest. Dermatol. 125, 659\u2013664 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"2320_CR38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361\u2013370 (1983).","journal-title":"Acta Psychiatr. Scand."},{"key":"2320_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","volume":"42","author":"C Herrmann","year":"1997","unstructured":"Herrmann, C. International experiences with the Hospital Anxiety and Depression Scale\u2014a review of validation data and clinical results. J. Psychosom. Res. 42, 17\u201341 (1997).","journal-title":"J. Psychosom. Res."},{"key":"2320_CR40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","volume":"158","author":"SG Kwatra","year":"2022","unstructured":"Kwatra, S. G. Prurigo nodularis. JAMA Dermatol. 158, 336 (2022).","journal-title":"JAMA Dermatol."},{"key":"2320_CR41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton, J. D. et al. Dupilumab supresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin. Exp. Allergy 51, 915\u2013931 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"2320_CR42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck, L. A. et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371, 130\u2013139 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2320_CR43","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt, A. et al. Long-term management of moderate-to severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389, 2287\u20132303 (2017).","journal-title":"Lancet"},{"key":"2320_CR44","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert, C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394, 1638\u20131650 (2019).","journal-title":"Lancet"},{"key":"2320_CR45","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378, 2475\u20132485 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2320_CR46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 155\u2013172 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2320_CR47","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","volume":"141","author":"M Belzberg","year":"2021","unstructured":"Belzberg, M. et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization. J. Invest. Dermatol. 141, 2208\u20132218 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"2320_CR48","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","volume":"39","author":"MR Mack","year":"2018","unstructured":"Mack, M. R. & Kim, B. S. The itch\u2013scratch cycle: a neuroimmune perspective. Trends Immunol. 39, 980\u2013991 (2018).","journal-title":"Trends Immunol."},{"key":"2320_CR49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/ejd.2010.1196","volume":"21","author":"K Park","year":"2011","unstructured":"Park, K., Mori, T., Nakamura, M. & Tokura, Y. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur. J. Dermatol. 21, 135\u2013136 (2011).","journal-title":"Eur. J. Dermatol."},{"key":"2320_CR50","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","volume":"165","author":"S Fukushi","year":"2011","unstructured":"Fukushi, S., Yamasaki, K. & Aiba, S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br. J. Dermatol. 165, 990\u2013996 (2011).","journal-title":"Br. J. Dermatol."},{"key":"2320_CR51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen, L. K. et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171, 217\u2013228 (2017).","journal-title":"Cell"},{"key":"2320_CR52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto, T. et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp. Dermatol. 30, 804\u2013810 (2021).","journal-title":"Exp. Dermatol."},{"key":"2320_CR53","doi-asserted-by":"crossref","unstructured":"Miron, Y. et al. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. J. Allergy Clin. Immunol. 150, 690\u2013700 (2022).","DOI":"10.1016\/j.jaci.2022.01.028"},{"key":"2320_CR54","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","volume":"142","author":"N Sutaria","year":"2022","unstructured":"Sutaria, N. et al. Cutaneous transcriptomic identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis. J. Invest. Dermatol. 142, 2537\u20132540 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"2320_CR55","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/exd.14401","volume":"30","author":"G Ingrasci","year":"2021","unstructured":"Ingrasci, G., Lipman, Z. M., Hawash, A. A., Girolomoni, G. & Yosipovitch, G. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp. Dermatol. 30, 1208\u20131217 (2021).","journal-title":"Exp. Dermatol."},{"key":"2320_CR56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","volume":"165","author":"B Schuhknecht","year":"2011","unstructured":"Schuhknecht, B. et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br. J. Dermatol. 165, 85\u201391 (2011).","journal-title":"Br. J. Dermatol."},{"key":"2320_CR57","doi-asserted-by":"crossref","first-page":"1011142","DOI":"10.3389\/fmed.2022.1011142","volume":"9","author":"V Parthasarathy","year":"2022","unstructured":"Parthasarathy, V. et al. Circulation plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis. Front. Med. (Lausanne) 9, 1011142 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"2320_CR58","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4049\/jimmunol.168.3.1139","volume":"168","author":"SP Atamas","year":"2002","unstructured":"Atamas, S. P., Luzina, I. G., Dai, H., Wilt, S. G. & White, B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J. Immunol. 168, 1139\u20131145 (2002).","journal-title":"J. Immunol."},{"key":"2320_CR59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","volume":"312","author":"JK Nguyen","year":"2020","unstructured":"Nguyen, J. K., Austin, E., Huang, A., Mamalis, A. & Jagdeo, J. The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch. Dermatol. Res. 312, 81\u201392 (2020).","journal-title":"Arch. Dermatol. Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02320-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:14:05Z","timestamp":1684757645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02320-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"23 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y.: Arcutis, Bellus Health, Eli Lilly, Escient Pharmaceuticals, Galderma, GSK, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, Trevi Therapeutics\u2014advisory board member; Eli Lilly, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer\u2014grants\/research funding; Regeneron Pharmaceuticals Inc., Sanofi\u2014investigator. N.M.: Boehringer Ingelheim, Galderma, Janssen, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Trevi Therapeutics\u2014advisory board member; Regeneron Pharmaceuticals Inc., Sanofi\u2014investigator. S.S.: Celldex Therapeutics, Clexio Biosciences, Dermasence, Galderma, GSK, Kiniksa Pharmaceuticals, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics\u2014investigator; AbbVie, Almirall, Beiersdorf, Bellus Health, Benevolent<sup>AI<\/sup>, Bionorica, Bristol Myers Squibb, Cara Therapeutics, Cello Health, Clexio Biosciences, DS Biopharma, Eli Lilly, Escient Pharmaceuticals, Galderma, Gr\u00fcnenthal, Kiniksa Pharmaceuticals, Klinge Pharma, Menlo Therapeutics, Perrigo, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, Siena Biopharmaceuticals, Trevi Therapeutics, Vanda Pharmaceuticals, Vifor Pharma, WebMD\u2014consultancy\/advisory board; Almirall, Beiersdorf, Eli Lilly, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Omnicuris, Pfizer, Pierre Fabre, Professor Paul Gerson Unna Academy, Sanofi\u2014speaker. S.G.K.: AbbVie, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Castle Creek Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi\u2014advisory board member\/consultant; Galderma, Incyte, Pfizer, Sanofi\u2014investigator. B.S.K.: AbbVie, Almirall, Amagma, Argenx, AstraZeneca, Bellus Health, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Daewoong Pharmaceutical, Eli Lilly, Genzyme, GSK, Guidepoint Global, Incyte, Janssen Pharmaceuticals, LEO Pharma A\/S, LEO Pharma, LectureLinx, OM Pharma, Pfizer, RecensMedical, Regeneron Pharmaceuticals Inc., Shaperon, Trevi Therapeutics, WebMD\u2014consultant; Locus Biosciences\u2014may hold stock and\/or stock options. E.L., L.P.M., H.W.S., N.P., S.W., G.S. and J.T.O: Sanofi\u2014employees and may hold stock and\/or stock options in the company. N.A.: Regeneron Pharmaceuticals Inc.\u2014former employee and shareholder and employee at the time research was performed. B.A., G.D.Y., D.M.W. and A.B.: Regeneron Pharmaceuticals Inc.\u2014employees and shareholders.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}